P. Grant

发表

Lymphovascular space invasion in early-stage endometrial cancer: adjuvant treatment and patterns of recurrence

R. Bekkers, D. Allen, E. van Barneveld, 2016 .

Phase II biomarker trial of a multimarker diagnostic for ovarian cancer

G. Rice, G. Barker, D. Allen, 2010, Journal of Cancer Research and Clinical Oncology.

Secondary Cytoreductive Surgery for Recurrent Epithelial Ovarian Cancer

V. Gebski, N. Hacker, E. Tay, 2002, Obstetrics and gynecology.

Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study.

A. deFazio, L. Na, L. Mileshkin, 2020, Gynecologic oncology.

Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study

M. Stockler, V. Gebski, M. Friedlander, 2013, Journal of gynecologic oncology.

The management of endometrial carcinoma

D. Allen, P. Grant, 2000, The Australian & New Zealand journal of obstetrics & gynaecology.

Oral cyclophosphamide in recurrent ovarian cancer

M. Quinn, L. Mileshkin, D. Rischin, 2016, Asia-Pacific journal of clinical oncology.

Abnormalities of the RB1 Pathway in Ovarian Serous Papillary Carcinoma as Determined by Overexpression of the p16(INK4A) Protein

M. de Silva, D. Venter, J. Armes, 2005, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Paclitaxel (Taxol * ) as Salvage Therapy for Relapsed Ovarian Cancer

A. Brand, P. Sykes, D. Allen, 1996, The Australian & New Zealand journal of obstetrics & gynaecology.

Pelvic radiation therapy for gynecologic malignancy in geriatric patients

J. F. Filbee, P. Grant, M. Tompkins, 1989, Gynecologic oncology.

Adjuvant treatment, tumour recurrence and the survival rate of uterine serous carcinomas: a single-institution review of 62 women

D. Allen, P. Grant, S. Hyde, 2015 .

The long-term follow-up of women with gestational diabetes.

J. Oats, N. Beischer, P. Grant, 1986, Australian and New Zealand journal of obstetrics and gynaecology.

Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer

B. Kiely, J. Hopper, R. Milne, 2011, Familial Cancer.

Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns).

A. deFazio, M. Friedlander, V. Beesley, 2021, Gynecologic oncology.

Squamous cell carcinoma of the vulva with bulky positive groin nodes—nodal debulking versus full groin dissection prior to radiation therapy

N. Hacker, J. Velden, M. Schilthuis, 2006, International Journal of Gynecologic Cancer.

Adjuvant small field pelvic radiation for patients with high risk, Stage IB lymph node negative cervix carcinoma after radical hysterectomy and pelvic lymph node dissection

N. Hacker, P. Grant, F. Kridelka, 1999, Cancer.

Ovarian Growing Teratoma Syndrome With Spuriously Elevated α-Fetoprotein.

D. Rischin, P. Grant, A. Pendlebury, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hypersensitivity reactions to carboplatin.

P. Grant, D. Timmins, R. Planner, 1991, Journal of the National Cancer Institute.

Corticosteroids in the management of bowel obstruction on a gynecological oncology unit.

N. Hacker, P. Grant, J. Philip, 1999, Gynecologic oncology.

EDITORIAL: Vulvar Cancer

P. Grant, 1995 .

Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors.

H. Burger, M. Quinn, J. Campbell, 1994, The New England journal of medicine.

Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor–Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer

A. deFazio, P. Beale, M. Friedlander, 2017, International Journal of Gynecologic Cancer.

The Long‐Term Follow‐up of Women with Gestational Diabetes

J. Oats, N. Beischer, P. Grant, 1986 .

Characterization of Blood Monocyte Phenotype in Patients With Endometrial Cancer

V. Apostolopoulos, C. McDonald, D. Pouniotis, 2011, International Journal of Gynecologic Cancer.

The Emergence of Diabetes and Impaired Glucose Tolerance in Women Who Had Gestational Diabetes

J. Oats, N. Beischer, P. Grant, 1988 .

Elevated Serum Inhibin Concentrations in Postmenopausal Women with Ovarian Tumors

H. Burger, M. Quinn, J. Campbell, 1993 .

Placental site trophoblastic tumor. Report of three cases and review of the literature

D. Fortune, J. Scurry, J. How, 1995, International Journal of Gynecologic Cancer.

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

Kylie L. Gorringe, S. Fox, P. Fasching, 2020, Modern Pathology.

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

S. Fox, K. Byth, S. Lade, 2018, Nature Communications.

A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer

M. Quinn, G. Pietersz, B. Loveland, 2014, Journal of Immunotherapy for Cancer.

The circulating microRNA-200 family in whole blood are potential biomarkers for high-grade serous epithelial ovarian cancer.

C. Whitehead, N. Hannan, S. Tong, 2017, Biomedical reports.

Unusual variants of vaginal adenosis: a challenge for diagnosis and treatment.

J. Scurry, P. Grant, R. Planner, 1991, Gynecologic oncology.

A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial.

N. Bradshaw, M. Friedlander, M. Hall, 2021, Gynecologic oncology.

Grapelike leiomyoma of the uterus.

J. Scurry, A. Brand, P. Grant, 1995, American journal of obstetrics and gynecology.

PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.

A. deFazio, P. Beale, F. Amant, 2019, Gynecologic oncology.

PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression

A. deFazio, P. Beale, F. Amant, 2019, Journal of gynecologic oncology.

High-dose medroxyprogesterone acetate in advanced ovarian cancer

M. Quinn, P. Grant, R. Rome, 1991, International Journal of Gynecologic Cancer.

Comparing the impact of dose reductions and delays on ovarian cancer patient outcomes with three-weekly versus dose dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort.

L. Mileshkin, M. Friedlander, P. Webb, 2018 .

Insomnia and its association with quality of life in women with ovarian cancer.

A. deFazio, M. Friedlander, V. Beesley, 2020, Gynecologic oncology.

Coping strategies, trajectories, and their associations with patient-reported outcomes among women with ovarian cancer

A. deFazio, M. Friedlander, V. Beesley, 2018, Supportive Care in Cancer.

Possible high‐grade squamous intraepithelial lesion (pHSIL) in the new cervical screening paradigm: The outcomes and the role of clinicopathological review

R. Hiscock, P. Grant, S. McGrath, 2021, The Australian & New Zealand journal of obstetrics & gynaecology.

Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer

K. Byth, S. Fox, S. Lade, 2014, Scientific Reports.

Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci

M. Beckmann, P. Fasching, E. Goode, 2017, Oncotarget.

Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci.

M. Beckmann, P. Fasching, E. Goode, 2017, Oncotarget.

Efficacy of dexamethasone in the management of malignant small bowel obstruction in advanced epithelial ovarian cancer

R. Hiscock, P. Grant, M. McGauran, 2021, Supportive Care in Cancer.

Incidence and Characteristics of Unsuspected Neoplasia Discovered in High-Risk Women Undergoing Risk Reductive Bilateral Salpingooophorectomy

P. Grant, S. Hyde, M. Newman, 2016, International Journal of Gynecologic Cancer.

Prognostic Value of Bilateral Positive Nodes in Squamous Cell Cancer of the Vulva

Guus Fons, Simon E Hyde, Marrije R Buist, 2008, International Journal of Gynecologic Cancer.

Pre- and Post-Diagnosis Diet Quality and Ovarian Cancer Survival

A. deFazio, M. Friedlander, P. Webb, 2020, Cancer Epidemiology, Biomarkers & Prevention.

A healthy lifestyle and survival among women with ovarian cancer

A. deFazio, M. Friedlander, J. Hansen, 2020, International journal of cancer.

Circulating 25-hydroxyvitamin D and survival in women with ovarian cancer.

P. Webb, T. Ibiebele, C. Nagle, 2015, The American journal of clinical nutrition.

Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer

B. Kiely, J. Hopper, R. Milne, 2017, Familial Cancer.

Common analgesics and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) Study

A. deFazio, M. Friedlander, S. Jordan, 2018, Journal of the National Cancer Institute.

Lymphatic ascites following lymphadenectomy for gynecological malignancy.

N. Hacker, P. Grant, G. Robertson, 2001, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Association of protein intake with recurrence and survival following primary treatment of ovarian cancer.

M. Friedlander, P. Webb, T. Ibiebele, 2023, The American journal of clinical nutrition.

Effects of Previous Surgery on the Detection of Sentinel Nodes in Women With Vulvar Cancer

R. Bekkers, D. Allen, P. Grant, 2011, International Journal of Gynecologic Cancer.

Benign endocervical cystic glandular change mimicking minimal deviation adenocarcinoma of the cervix on magnetic resonance imaging: A case report

M. Quinn, A. Dobrotwir, D. Neesham, 2004, Australian and New Zealand journal of obstetrics and gynaecology.

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

S. Fox, S. Lade, N. Traficante, 2018, Nature Communications.

Ovarian Growing Teratoma Syndrome With Spuriously Elevated α-Fetoprotein.

D. Rischin, P. Grant, A. Pendlebury, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Maximum Effort in the Management of Ovarian Cancer, Including Pelvic and Para‐aortic Lymphadenectomy

D. Allen, P. Grant, R. Planner, 1992, The Australian & New Zealand journal of obstetrics & gynaecology.